Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: A sarah cannon oncology research consortium phase ii trial

Clinical Genitourinary Cancer

Volumn 11, Issue 3, 2013, Pages 270-275

  Hainsworth, John D ^a,b   Rubin, Mark S ^c   Arrowsmith, Edward R ^d   Khatcheressian, James ^e   Crane, Edward J ^f   Franco, Luis A ^g  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Florida Cancer Specialists   (United States)

^d Chattanooga Oncology Hematology Associates   (United States)

^e Virginia Cancer Institute   (United States)

^f Oncology Hematology Care Inc   (United States)

^g Watson Clinic   (United States)

Author keywords

Pazopanib; Renal cell carcinoma; Sequential therapy; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; PAZOPANIB; SUNITINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SPEECH DISORDER; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR VOLUME; VOMITING; WEAKNESS; WOUND COMPLICATION;

PAZOPANIB; RENAL CELL CARCINOMA; SEQUENTIAL THERAPY; TYROSINE KINASE INHIBITORS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84883453765     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.04.006     Document Type: Article

References (17)

1. R.J. Motzer, T.E. Hutson, P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
2. B. Escudier, T. Eisen, W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
3. B. Escudier, A. Pluzanska, P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
4. C.N. Sternberg, I.D. Davis, J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
5. B.I. Rini, P. Escudier, A. Tomczak Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of a phase III AXIS trial J Clin Oncol 29 suppl 2011 289 abstract 4503
6. B. Escudier, J. Bellmunt, S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
7. B.I. Rini, M.D. Michaelson, J.E. Rosenberg Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 2008 3743 3748
8. B.I. Rini, G. Wilding, G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
9. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
10. E. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
11. R.J. Motzer, M. Mazumdar, J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
12. R.M. Bukowski, F.F. Kabbinavar, R.A. Figlin Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J Clin Oncol 25 2007 4536 4541
13. J.D. Hainsworth, D.R. Spigel, H.A. Burris Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J Clin Oncol 28 2010 2131 2136
14. D.M. Waterhouse, W.C. Penley, C.D. Webb Sorafenib and everolimus (RAD001) in the treatment of patients with advanced clear cell renal carcinoma (RCC): a Sarah Cannon Research Institute phase I/II trial J Clin Oncol 29 suppl 2011 320 abstract 4629
15. D.R. Feldman, M.S. Baum, M.S. Ginsberg Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1432 1439
16. R. Kumar, V.B. Knick, S.K. Rudolph Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol Cancer Ther 6 2007 2012 2021
17. B.I. Rini, S. Halabi, J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428